Enrico Martin

19 Introduction and thesis outline References 1. Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res . 2013;33(6):2597-2604. 2. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg . 2014;260(3):412-416. doi:10.1097/SLA.0000000000000869 3. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg . 2009;249(6):1014-1022. doi:10.1097/ SLA.0b013e3181a77e9a 4. Stucky C-CH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol . 2012;19(3):878-885. doi:10.1245/s10434-011-1978-7 5. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer . 2006;107(5):1065-1074. doi:10.1002/cncr.22098 6. Miao R, Wang H, Jacobson A , et al. Radiation -induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol . 2019;137:61-70. doi:10.1016/j.radonc.2019.03.015 7. Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet . 2002;39(5):311-314. 8. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral ner ve sheath tumors in neurofibromatosis. Cancer Res . 2002;62(5):1573-1577. 9. Uusitalo E, Leppävirta J, Koffert A, et al. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol . 2015;135(3):904-906. doi:10.1038/ jid.2014.465 10. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol . 2005;23(33):8422-8430. doi:10.1200/ JCO.2005.01.4886 11. Watson KL, Al Sannaa GA, Kivlin CM, et al. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg . 2017;126(1):319-329. doi:10.3171/2015.12.JNS152443 12. Valentin T, Cesne A Le, Ray-coquard I, Italiano A. ScienceDirect Management and prognosis of malignant peripheral nerve sheath tumors : The experience of the French Sarcoma Group ( GSF-GETO ). Eur J Cancer . 2016;56:77-84. doi:10.1016/j. ejca.2015.12.015 13. Zehou O, Bularca S, Bastuji-Garin S, et al. Neurofibromatosis 1 phenotype associated to malignant peripheral nerve sheath tumours: A case-control study. J Eur Acad Dermatology Venereol . 2013;27(8):1044-1047. doi:10.1111/j.1468- 3083.2012.04485.x 14. Martin E, Coert JH, Flucke UE, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer . 2019;124:77-87. doi:10.1016/j. ejca.2019.10.014 15. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer . 2016;56:77-84. doi:10.1016/j.ejca.2015.12.015 1